Literature DB >> 12147423

(223)Ra targets skeletal metastases and spares normal tissue.

Cathel Kerr.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12147423     DOI： 10.1016/s1470-2045(02)00835-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

1.  A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary.

Authors:  Zs Küronya; I Sinkovics; P Ágoston; K Bíró; I Bodrogi; I Böde; M Dank; F Gyergyay; T Vajdics; Zs Kolonics; K Nagyiványi; Á Rúzsa; L Géczi
Journal:  Pathol Oncol Res       Date:  2017-01-10       Impact factor: 3.201

2.  Ado-trastuzumab emtansine and radium 223 dichloride.

Authors:  Dominic A Solimando; J Aubrey Waddell
Journal:  Hosp Pharm       Date:  2013-10

3.  The elements of life and medicines.

Authors:  Prinessa Chellan; Peter J Sadler
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2015-03-13       Impact factor: 4.226

4.  Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.

Authors:  Megan A McNamara; Daniel J George
Journal:  BMC Cancer       Date:  2015-05-07       Impact factor: 4.430

5.  A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease.

Authors:  Robert Coleman; Anne-Kirsti Aksnes; Bjørn Naume; Camilo Garcia; Guy Jerusalem; Martine Piccart; Nancy Vobecky; Marcus Thuresson; Patrick Flamen
Journal:  Breast Cancer Res Treat       Date:  2014-04-13       Impact factor: 4.872

Review 6.  Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.

Authors:  Nihar K Patel; Antoine Finianos; Kristen D Whitaker; Jeanny B Aragon-Ching
Journal:  Ther Clin Risk Manag       Date:  2014-08-16       Impact factor: 2.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.